Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ischemic Heart Disease

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 65 articles:
HTML format
Text format



Single Articles


    May 2017
  1. RUTTY GN, Morgan B, Robinson C, Raj V, et al
    Diagnostic accuracy of post-mortem CT with targeted coronary angiography versus autopsy for coroner-requested post-mortem investigations: a prospective, masked, comparison study.
    Lancet. 2017 May 24. pii: S0140-6736(17)30333.
    PubMed     Text format     Abstract available


    April 2017
  2. KOOPMAN JJE, Kuipers RS
    From arterial ageing to cardiovascular disease.
    Lancet. 2017;389:1676-1678.
    PubMed     Text format    


  3. KAHAN T
    Target blood pressure in patients at high cardiovascular risk.
    Lancet. 2017 Apr 5. pii: S0140-6736(17)30935.
    PubMed     Text format    


  4. BOHM M, Schumacher H, Teo KK, Lonn EM, et al
    Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Lancet. 2017 Apr 5. pii: S0140-6736(17)30754.
    PubMed     Text format     Abstract available


  5. VIDAL-PETIOT E, Bhatt DL, Fox KM, Steg PG, et al
    Blood pressure and cardiovascular outcomes: a closer look - Authors' reply.
    Lancet. 2017;389:1296-1297.
    PubMed     Text format    


  6. WALD NJ, Wald DS
    Blood pressure and cardiovascular outcomes: a closer look.
    Lancet. 2017;389:1296.
    PubMed     Text format    


  7. DOUMAS M, Stavropoulos KV, Boutari C, Imprialos KP, et al
    Blood pressure and cardiovascular outcomes: a closer look.
    Lancet. 2017;389:1295-1296.
    PubMed     Text format    


    March 2017
  8. SCHOOLING CM
    Tachykinin neurokinin 3 receptor antagonists: a new treatment for cardiovascular disease?
    Lancet. 2017 Mar 27. pii: S0140-6736(16)31648.
    PubMed     Text format     Abstract available


  9. GURBEL PA, Tantry US
    GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes.
    Lancet. 2017 Mar 17. pii: S0140-6736(17)30760.
    PubMed     Text format    


  10. OHMAN EM, Roe MT, Steg PG, James SK, et al
    Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Lancet. 2017 Mar 17. pii: S0140-6736(17)30751.
    PubMed     Text format     Abstract available


  11. KAPLAN H, Thompson RC, Trumble BC, Wann LS, et al
    Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study.
    Lancet. 2017 Mar 16. pii: S0140-6736(17)30752.
    PubMed     Text format     Abstract available


  12. THE LANCET
    Polypills: an essential medicine for cardiovascular disease.
    Lancet. 2017;389:984.
    PubMed     Text format    


  13. HUFFMAN MD, Xavier D, Perel P
    Uses of polypills for cardiovascular disease and evidence to date.
    Lancet. 2017;389:1055-1065.
    PubMed     Text format     Abstract available


    January 2017
  14. BLACHER J, Levy BI, Mourad JJ, Safar ME, et al
    Hypertension control and cardiovascular disease - Authors' reply.
    Lancet. 2017;389:154-155.
    PubMed     Text format    


  15. JAMES JE
    Hypertension control and cardiovascular disease.
    Lancet. 2017;389:154.
    PubMed     Text format    


  16. MESSERLI FH, Fischer U, Rimoldi SF, Bangalore S, et al
    Hypertension control and cardiovascular disease.
    Lancet. 2017;389:153.
    PubMed     Text format    


  17. TAWAKOL A, Ishai A, Takx RA, Figueroa AL, et al
    Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study.
    Lancet. 2017 Jan 12. pii: S0140-6736(16)31714.
    PubMed     Text format     Abstract available


    November 2016
  18. COLLINS R, Reith C, Emberson J, Armitage J, et al
    Interpretation of the evidence for the efficacy and safety of statin therapy.
    Lancet. 2016;388:2532-2561.
    PubMed     Text format     Abstract available


    October 2016
  19. MAKIKALLIO T, Holm NR, Lindsay M, Spence MS, et al
    Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32052.
    PubMed     Text format     Abstract available


  20. MACK M, Holmes DR
    Randomised trials in left main disease: a NOBLE effort.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32067.
    PubMed     Text format    


  21. VON BIRGELEN C, Kok MM, van der Heijden LC, Danse PW, et al
    Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)31920.
    PubMed     Text format     Abstract available


  22. FINN AV, Virmani R
    Biodegradable polymer drug-eluting stents: non-inferiority waiting for superiority?
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32063.
    PubMed     Text format    


  23. ALI ZA, Maehara A, Genereux P, Shlofmitz RA, et al
    Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)31922.
    PubMed     Text format     Abstract available


  24. SERRUYS PW, Chevalier B, Sotomi Y, Cequier A, et al
    Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32050.
    PubMed     Text format     Abstract available


  25. ROSSIGNOL P, Pitt B, Thompson A, Zannad F, et al
    Roadmap for cardiovascular prevention trials in chronic kidney disease.
    Lancet. 2016;388:1964-1966.
    PubMed     Text format    


  26. GUAN WJ, Zheng XY, Chung KF, Zhong NS, et al
    Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action.
    Lancet. 2016;388:1939-1951.
    PubMed     Text format     Abstract available


  27. ISAAZ K, Gerbay A
    Deferred stenting in acute ST elevation myocardial infarction.
    Lancet. 2016;388:1371.
    PubMed     Text format    


  28. KELBAEK H, Hofsten DE, Engstrom T, Helqvist S, et al
    Deferred stenting in acute ST elevation myocardial infarction - Authors' reply.
    Lancet. 2016;388:1371-1372.
    PubMed     Text format    


  29. WONG EM, Chair SY, Leung DY, Sit JW, et al
    The effect of an e-health web-based support programme on psychological outcomes and health related quality of life among Chinese patients with coronary heart disease: a parallel-group randomised controlled trial.
    Lancet. 2016;388 Suppl 1:S86.
    PubMed     Text format     Abstract available


    September 2016
  30. FEINBERG MW
    No small task: therapeutic targeting of Lp(a) for cardiovascular disease.
    Lancet. 2016 Sep 21. pii: S0140-6736(16)31329.
    PubMed     Text format    


    August 2016
  31. CAYLA G, Cuisset T, Silvain J, Leclercq F, et al
    Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31323.
    PubMed     Text format     Abstract available


  32. VIDAL-PETIOT E, Ford I, Greenlaw N, Ferrari R, et al
    Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31326.
    PubMed     Text format     Abstract available


  33. MANCIA G
    Should blood pressure reduction be aggressive in patients with hypertension and coronary artery disease?
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31398.
    PubMed     Text format    


  34. WEINTRAUB WS
    Invasive management of acute coronary syndromes.
    Lancet. 2016 Aug 25. pii: S0140-6736(16)31273.
    PubMed     Text format    


  35. WALLENTIN L, Lindhagen L, Arnstrom E, Husted S, et al
    Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study.
    Lancet. 2016 Aug 25. pii: S0140-6736(16)31276.
    PubMed     Text format     Abstract available


  36. REED GW, Rossi JE, Cannon CP
    Acute myocardial infarction.
    Lancet. 2016 Aug 5. pii: S0140-6736(16)30677.
    PubMed     Text format     Abstract available


    July 2016
  37. SNYDER A
    Philip Majerus.
    Lancet. 2016;388:458.
    PubMed     Text format    


  38. KAIN K
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:126.
    PubMed     Text format    


  39. ETTEHAD D, Emdin CA, Kiran A, Rahimi K, et al
    Blood pressure lowering for cardiovascular disease - Authors' reply.
    Lancet. 2016;388:126-7.
    PubMed     Text format    


  40. O'KEEFFE DT, Maraka S
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125.
    PubMed     Text format    


  41. SMULDERS YM, Muller M
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125-6.
    PubMed     Text format    


  42. COLLINS DR, Albasri A, O'Sullivan J, Bobrovitz N, et al
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125.
    PubMed     Text format    


  43. STONE GW, Gao R, Kimura T, Simonton C, et al
    Optimum technique to reduce risk of stent thrombosis - Authors' reply.
    Lancet. 2016;388:127-8.
    PubMed     Text format    


  44. SHAH R
    Optimum technique to reduce risk of stent thrombosis.
    Lancet. 2016;388:127.
    PubMed     Text format    


    June 2016
  45. GLADWIN MT
    Cardiovascular complications and risk of death in sickle-cell disease.
    Lancet. 2016;387:2565-74.
    PubMed     Text format     Abstract available


  46. TEGN N, Abdelnoor M, Aaberge L, Endresen K, et al
    Invasive strategy in acute coronary syndrome - Authors' reply.
    Lancet. 2016;387:2504.
    PubMed     Text format    


  47. MATHEW ST, Pakala AV, Thadani U
    Invasive strategy in acute coronary syndrome.
    Lancet. 2016;387:2503-4.
    PubMed     Text format    


  48. SHAH R
    Invasive strategy in acute coronary syndrome.
    Lancet. 2016;387:2503.
    PubMed     Text format    


  49. TIMMIS A
    Invasive strategy in acute coronary syndrome.
    Lancet. 2016;387:2503.
    PubMed     Text format    


  50. POVSIC TJ, Zeiher AM
    IxCELL-DCM: rejuvenation for cardiac regenerative therapy?
    Lancet. 2016;387:2362-3.
    PubMed     Text format    


  51. FUJITA T
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2289.
    PubMed     Text format    


  52. FORD C, Whitehead SJ, Gama R, Willmer KA, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2289.
    PubMed     Text format    


  53. SHAH AS, Anand A, Chapman AR, Newby DE, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction - Authors' reply.
    Lancet. 2016;387:2289-91.
    PubMed     Text format    


  54. BOEDDINGHAUS J, Twerenbold R, Nestelberger T, Wildi K, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2288.
    PubMed     Text format    


  55. MULLEN L, Chew PG, Frost F, Obafemi T, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2288-9.
    PubMed     Text format    


  56. DALE A, Slade E, Heneghan C
    Outcomes reporting of the FAME trial.
    Lancet. 2016;387:2292.
    PubMed     Text format    


    May 2016
  57. LAFONT A, Mennuni MG
    Effect on death of scaffold thrombosis versus stent thrombosis.
    Lancet. 2016;387:2198.
    PubMed     Text format    


  58. KAUFMAN JD, Adar SD, Barr RG, Budoff M, et al
    Association between air pollution and coronary artery calcification within six metropolitan areas in the USA (the Multi-Ethnic Study of Atherosclerosis and Air Pollution): a longitudinal cohort study.
    Lancet. 2016 May 24. pii: S0140-6736(16)00378.
    PubMed     Text format     Abstract available


  59. MENTE A, O'Donnell M, Rangarajan S, Dagenais G, et al
    Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies.
    Lancet. 2016 May 20. pii: S0140-6736(16)30467.
    PubMed     Text format     Abstract available


  60. SABATE M, Brugaletta S
    Outcomes in the EXAMINATION trial - Authors' reply.
    Lancet. 2016;387:1998.
    PubMed     Text format    


  61. DRYSDALE H, Hartley P, Goldacre B
    Outcomes in the EXAMINATION trial.
    Lancet. 2016;387:1997-8.
    PubMed     Text format    


  62. CASSESE S, Kastrati A
    Risk of stent thrombosis with bioresorbable vascular scaffolds - Authors' reply.
    Lancet. 2016;387:1904.
    PubMed     Text format    


  63. SHAH R, Ramos-Bondy B, Mizeracki A
    Risk of stent thrombosis with bioresorbable vascular scaffolds.
    Lancet. 2016;387:1903.
    PubMed     Text format    


    April 2016
  64. VESTBO J, Anderson JA, Brook RD, Calverley PM, et al
    Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
    Lancet. 2016;387:1817-1826.
    PubMed     Text format     Abstract available


  65. VAN 'T HOF AW, Ottervanger JP
    Primary angioplasty for STEMI: hard to improve upon.
    Lancet. 2016 Apr 1. pii: S0140-6736(16)30123.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: